Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Milacemide therapy for Parkinson's disease

M E Giuffra1, V H Sethy, T L Davis

  • 1Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.

Movement Disorders : Official Journal of the Movement Disorder Society
|January 1, 1993
PubMed
Summary

Milacemide, a glycine prodrug, temporarily worsened Parkinson's disease symptoms, particularly rigidity, in a small study. It did not affect levodopa-induced dyskinesias, suggesting complex roles for glutamatergic drugs in movement disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contact sex pheromone in the tsetse flyGlossina pallidipes (Austen) Identification and Synthesis.

Journal of chemical ecology·2013
Same author

Compared behavioral responses of maleDrosophila melanogaster (Canton S) to natural and synthetic aphrodisiacs.

Journal of chemical ecology·2013
Same author

Mobility, mood and site of care impact health related quality of life in Parkinson's disease.

Parkinsonism & related disorders·2013
Same author

Size distribution effects of cadmium tellurium quantum dots (CdS/CdTe) immunotoxicity on aquatic organisms.

Environmental science. Processes & impacts·2013
Same author

Deep brain stimulation in early Parkinson's disease: enrollment experience from a pilot trial.

Parkinsonism & related disorders·2011
Same author

Effects of prostaglandin E and F receptor agonists in vivo on luteal function in ewes.

Prostaglandins & other lipid mediators·2010

Area of Science:

  • Neuroscience
  • Pharmacology
  • Movement Disorders

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder affecting motor function.
  • The glutamatergic system plays a role in motor control and is implicated in PD.
  • Milacemide is a glycine prodrug designed to stimulate central glutamatergic pathways.

Purpose of the Study:

  • To investigate the clinical effects of central glutamatergic stimulation using milacemide in Parkinson's disease patients.
  • To assess the impact of milacemide on overall parkinsonian severity and levodopa-induced dyskinesias.

Main Methods:

  • A double-blind, placebo-controlled study involving six patients with Parkinson's disease.
  • Administration of milacemide as monotherapy at a single oral dose of 1,200 mg.

Related Experiment Videos

  • Evaluation of clinical effects on parkinsonian symptoms and dyskinesias.

    • Main Results:

    • Milacemide administration resulted in a transient increase in overall parkinsonian severity.
    • The primary effect was observed on rigidity, which worsened following milacemide treatment.
    • Milacemide did not significantly alter the severity of levodopa-induced dyskinesias.

    Conclusions:

    • Central glutamatergic stimulation with milacemide can influence motor function in patients with extrapyramidal movement disorders like Parkinson's disease.
    • These findings suggest that modulating the glutamatergic system may impact parkinsonian symptoms.
    • Further research into selective glutamate receptor antagonists may offer therapeutic potential for Parkinson's disease.